Table Graph
      published meta-analysis   sensitivity analysis   studies

umifenovir (arbidol) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsNojomi, 2020 0.49 [0.04; 5.58] Nojomi, 2020 (REV) 0.49 [0.04; 5.58] 0.49[0.09; 2.74]Nojomi, 2020, Nojomi, 2020 (REV)20%200moderatenot evaluable viral clearance by day 14detailed resultsELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38] 1.84[0.40; 8.38]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable viral clearance by day 7detailed resultsELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89] 1.08[0.41; 2.89]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable severe COVID-19 occurrencedetailed resultsELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27] 0.30[0.07; 1.27]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-04 00:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 516 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons